Introduction: the problem of antibiotic resistance
In recent years the world has been facing two important and linked problems: i) the emergence and spread of antibiotic resistance in pathogenic bacteria and ii) failure to discover new chemotherapeutic agents. Antibiotic resistance in pathogenic bacteria does 35 not only generate an important economic burden for the healthcare system, but also reduces the efficacy of antibiotics and increases mortality. Thus, antibiotic resistance is considered a worldwide threat for human health, since once treatable infections may be fatal again. There was a time in which clinics were revolutionized by the introduction of antibiotics, which enabled the treatment of infections and the performance of invasive 40 surgeries without fear. Those times have come to an end, and we have already entered into what is called the "resistance era" (1).
The "antibiotic era" started with the discovery of penicillin and sulfonamides in the late 1920s and 1930s. A "Golden Age" for antibiotic discovery then started, which continued until the 1960s. In that period, most of the antibiotic classes used today were 45 discovered. Penicillin, the first antibiotic of natural origin commercialized, was discovered in 1928 by Alexander Fleming (2) . After the introduction of penicillin into clinics in the 1940s, its extensive use against Streptococcus pneumoniae led to the first report on a penicillin-resistant strain in 1967 (3) . But the development of resistance had been observed before, as Fleming advertised in his Nobel Prize speech in 1945. He had 50 noted that penicillin resistant microbes were obtained easily in the laboratory, and warned that the same thing might occur in the human body.
Antibiotic resistance is a result of Darwinian selection, and there are no examples of antibiotics to which bacteria have not developed resistance within a few years of their use; being the emergence of resistance to the last-resort antibiotic, colistin, one of the 55 latest examples (4) (5) (6) . Resistance to antibiotics can be gained by mutations or acquisition of antibiotic resistance genes. In the latter, horizontal gene transfer by conjugation is considered the most important mechanism, although others processes (such as transformation or phage-mediated transduction) might play a larger part than previously expected; recently reviewed by von Wintersdorff and co-workers (7) . The 60 spontaneous generation of resistant strains by mutations, even before any exposure to the antibiotic, is a phenomenon known since 1955 (8) .
A large number of resistance genes of clinical relevance reportedly have their origin in non-pathogenic bacteria (7) . In fact, antibiotic resistance genes are as ancient as the biosynthetic equivalents, and have been detected in the DNA of 30,000-year-old 65 permafrost samples, as well as in the microbiome of caves that have been isolated for millions of years (9, 10) . In spite of being a natural process, the threat of antibiotic resistance is increasingly alarming because of the acceleration of its rate of appearance.
The main factor for this acceleration is the misuse of antibiotics through excessive use in human and veterinary clinics, and as growth promoters in farming. This excessive use 70 has led to an increased transmission of resistance elements that has facilitated the selection of resistant bacteria.
According to the Center for Disease Control and Prevention (CDC), it is estimated that more than 2 million people are infected with antibiotic resistant microbes in one year in the USA and, of them, more than 23,000 die due to the infection. The prognostics for 75 the future are also alarming; in 2050, 10 million deaths per year are predicted worldwide due to antibiotic resistance (11) . Thus, it is clear that the correct use of antibiotics is necessary to slow down the rate of the emergence of drug resistance, and that a new arsenal of antibiotics is urgently required. However, the introduction of new chemotherapeutics into clinical practice has been very slow and only one antibiotic from a new family, named teixobactin, has been discovered recently (see below). To overtake this problem, several drugs that were discarded in the past are currently gaining attention. For example fidaxomycin, originally discovered in the 1970s, was approved for use in 2011 by the US Food and Drug Administration (FDA), and has been successfully applied to the treatment of Clostridium difficile in recent years (12, 13).
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Ancient remedies and natural medicine are also gaining attention for the treatment of infections. For example, an "ancientbiotic" from the 10 th century has been proven to be effective against Staphylococcus aureus (14) . Similarly, a natural clay from Canada has been shown to act as a potent antibacterial against multi drug-resistant ESKAPE strains, an acronym referring to Enterococcus faecium, S. aureus, Klebsiella pneumoniae,
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Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species, which are all important pathogens responsible for nosocomial infections around the world (15, 16).
Cell-wall as an antibiotic target
The majority of antimicrobials used currently target the bacterial DNA, RNA, protein or 95 cell-wall biosynthesis. In this section we will focus on drugs acting on the biosynthesis of the main component of the cell-wall, peptidoglycan (PG). PG is a polymer composed of glycan strands crosslinked by peptides. These glycan strands are formed by alternating units of N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc). MurNAc is associated with peptides responsible for crosslinking the PG 100 strands. The crosslink between peptide chains can be direct (in most Gram-negative bacteria) or indirect, through an interpeptide bridge (in most Gram-positive bacteria). It is important to note that variations in PG composition exist depending on the species, for example regarding glycan chain length, the nature of the residues in the peptide stem or the length and nature of the residues in the cross-linking bridge (17, 18) . In all cases, catalyzed by penicillin-binding proteins (PBPs). These enzymes receive this acronym because they are able to bind penicillin. Please refer to the work by Sauvage and coworkers (22) for an in-depth review about PBPs structure and role on PG biosynthesis.
The majority of chemotherapeutic agents used in the clinic inhibit the lipid-linked steps of the PG synthetic pathway (see Figure 1 ), although the cytoplasmic steps are also Regarding the membrane-linked steps of PG biosynthesis, the complex moenomycin (also known as flavomycin) and the antibiotic ramoplanin inhibit the transglycosylation steps (37, 38). Moenomycin is used for animal feeding and has been reported to be effective against Helicobacter pylori (39) . Ramoplanin shows potent The structures of the main compounds cited in this work are depicted in Figure 2 .
Mechanisms of glycopeptide resistance and transcriptional regulation
The unique mode of action of glycopeptide antibiotics was promising and therefore a 235 slow development of resistances in pathogenic bacteria was expected. In fact, it took over 30 years after the introduction into the clinic to find the first vancomycin-resistant enterococci (VRE) strains (72, 73) . This is a very long period in comparison to the emergence of other cases of antibiotic resistance. Nowadays, VRE have become significant nosocomial pathogens worldwide, mainly due to their adaptability in hospital responding to Pi starvation is the Pho regulon, which constitutes a very efficient and sensible regulatory mechanism in bacteria.
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The Pho regulon was first characterised in E. coli, and later in many other bacterial species (96). It is controlled by a two-component regulatory system comprising an inner-membrane histidine kinase sensor protein (PhoR) and a cytoplasmic transcriptional response regulator, named PhoB in E. coli and PhoP in Bacillus subtilis (97, 98 
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In all cases, upon Pi scarcity the response regulator is phosphorylated on an aspartic acid residue by the sensor kinase. The phosphorylated response regulator is able to bind to specific sequences on the DNA and activate or repress the transcription of the target genes. These specific sequences, known as PHO boxes, were first characterized in E.
coli (106) . In most bacteria the PHO boxes are defined as 11-nucleotide sequences 335 composed of seven well conserved and four less conserved nucleotides (107). The PHO boxes are normally found in genes encoding extracellular enzymes capable of obtaining Pi from organic phosphates, Pi-specific transporters and enzymes involved in storage and saving of the nutrient. However, these sequences have also been found in a wide range of other genes that are not directly related to Pi metabolism, revealing a 340 surprisingly diverse role for the Pho regulon, not only as a regulator of Pi assimilation, but also as a master regulator of the cell (108) . Indeed, the Pho regulon is involved in regulation of nutritional cross-talk, secondary metabolite production and pathogenesis, among other important cell processes (109). 
Links between the Pho regulon and pathogenesis

Glycopeptide resistance is highly influenced by Pi.
A considerable number of studies have reported that the biosynthesis of most antibiotics is regulated by Pi; reviewed by Martín (121) . There are also studies that establish links between Pi regulation and antibiotic resistance. For instance, oxytetracycline production (165, 166) . A summary of the link between stress response regulators and glycopeptide resistance is shown in table 1.
b) Autolytic activity
The complexities of the regulation of autolytic activity versus glycopeptide resistance 515 are manifested by many examples in the scientific literature. For example, it has been noted that the autolytic activity of some glycopeptide-intermediate S. aureus strains (GISA) is reduced compared to that of the glycopeptide-susceptible strains (167) . In this sense, vancomycin-dependent inhibition of cell-wall turnover and autolysis was 23 described in a highly vancomycin-resistant S. aureus mutant, resulting in the 520 accumulation of cell-wall material and the inhibition of daughter cell separation (168).
Vancomycin was also described to block the in vitro hydrolysis of cell-walls by autolytic enzyme extracts and some lytic enzymes such as lysostaphin and mutanolysin.
Furthermore, it has been reported that decreased autolytic activity is involved in the reduced tolerance of a series of GISA isolates to vancomycin (169) . All together, these 525 findings indicate an important interconnection between glycopeptide resistance and cellwall lytic activity.
c) Antibiotic synthesis
Glycopeptide antibiotics also affect other important cellular processes, such as antibiotic synthesis. This is not unexpected since antimicrobials themselves are growth-inhibiting vancomycin, as well as a significant increase in the antibiotic production yields in a highly vancomycin-resistant mutant strain (see Figure 4) . 
